Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001354488-16-008627
Filing Date
2016-12-06
Accepted
2016-12-06 15:26:01
Documents
1
Period of Report
2016-12-02

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT issuerdirect_section16.html 4  
1 PRIMARY DOCUMENT issuerdirect_section16.xml 4 4811
  Complete submission text file 0001354488-16-008627.txt   6655
Mailing Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 20100
Business Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 20100 972-4-988-9488
Protalix BioTherapeutics, Inc. (Issuer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 101 HUNTINGTON AVENUE SUITE 2101 BOSTON MA 02199
Business Address 101 HUNTINGTON AVENUE SUITE 2101 BOSTON MA 02199 617-717-6600
Camber Capital Management LLC (Reporting) CIK: 0001444043 (see all company filings)

State of Incorp.: MA | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-33357 | Film No.: 162036202